As threatened last week, Valeant Pharmaceuticals International Inc. is moving to replace Cephalon Inc.'s board of directors following a rejection of its $5.7 billion hostile takeover bid. And the big pharma isn't taking "no" as a final answer: It's putting the question to Cephalon stockholders.